Literature DB >> 10971418

Lymphoedema following surgery for breast cancer.

S J Pain1, A D Purushotham.   

Abstract

BACKGROUND: Lymphoedema is a common complication of breast cancer treatment, affecting approximately a quarter of patients. Those affected can have an uncomfortable, unsightly and sometimes functionally impaired limb prone to episodes of superficial infection. The aetiology, pathophysiology and management of these patients is poorly understood.
METHODS: This is a systematic review of all published literature on lymphoedema following treatment for breast cancer, using the Medline and Cinahl databases with cross-referencing of major articles on the subject up to the end of 1999. RESULTS AND
CONCLUSION: The aetiology and pathophysiology of lymphoedema in patients with breast cancer appear to be multifactorial and are still not fully understood. Although conservative treatment techniques can be very successful in controlling symptoms, they do not afford a cure. The place of surgical and pharmacological therapy remains unclear. Improved understanding of the pathophysiology may assist in reducing the incidence of this condition, or help to identify those at greatest risk, in whom early initiation of conservative treatment measures may prove effective.

Entities:  

Mesh:

Year:  2000        PMID: 10971418     DOI: 10.1046/j.1365-2168.2000.01569.x

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  15 in total

1.  Can ICF model for patients with breast-cancer-related lymphedema predict quality of life?

Authors:  Jau-Yih Tsauo; Hsiu-Chuan Hung; Han-Ju Tsai; Chiun-Sheng Huang
Journal:  Support Care Cancer       Date:  2010-04-06       Impact factor: 3.603

2.  Risk factors for lymphedema after breast cancer treatment.

Authors:  Sandra A Norman; A Russell Localio; Michael J Kallan; Anita L Weber; Heather A Simoes Torpey; Sheryl L Potashnik; Linda T Miller; Kevin R Fox; Angela DeMichele; Lawrence J Solin
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-10-26       Impact factor: 4.254

3.  A pilot randomized trial evaluating low-level laser therapy as an alternative treatment to manual lymphatic drainage for breast cancer-related lymphedema.

Authors:  Sheila H Ridner; Ellen Poage-Hooper; Collin Kanar; Jennifer K Doersam; Stewart M Bond; Mary S Dietrich
Journal:  Oncol Nurs Forum       Date:  2013-07       Impact factor: 2.172

Review 4.  Lymph Node Radiotherapy Instead of Extended Axillary Surgery - the New Standard?

Authors:  Peter Niehoff; Silla Hey-Koch
Journal:  Breast Care (Basel)       Date:  2018-06-06       Impact factor: 2.860

5.  Breast cancer-related lymphedema: women's experiences with an underestimated condition.

Authors:  Roanne Thomas-MacLean; Baukje Miedema; Sue R Tatemichi
Journal:  Can Fam Physician       Date:  2005-02       Impact factor: 3.275

Review 6.  Exercise and the lymphatic system: implications for breast-cancer survivors.

Authors:  Kirstin Lane; Dan Worsley; Don McKenzie
Journal:  Sports Med       Date:  2005       Impact factor: 11.136

7.  The role of occupational upper extremity use in breast cancer related upper extremity lymphedema.

Authors:  Gulgun Tahan; Ronald Johnson; Lisa Mager; Atilla Soran
Journal:  J Cancer Surviv       Date:  2009-12-06       Impact factor: 4.442

8.  Pneumatic compression devices for in-home management of lymphedema: two case reports.

Authors:  Samantha Cannon
Journal:  Cases J       Date:  2009-03-23

Review 9.  The treatment of lymphedema related to breast cancer: a systematic review and evidence summary.

Authors:  Lyn Kligman; Rebecca K S Wong; Mary Johnston; Nancy S Laetsch
Journal:  Support Care Cancer       Date:  2004-04-17       Impact factor: 3.603

10.  Predicting recreational difficulties and decreased leisure activities in women 6-12 months post breast cancer surgery.

Authors:  Baukje Miedema; Ryan Hamilton; Sue Tatemichi; Roanne Thomas-MacLean; Anna Towers; Thomas F Hack; Andrea Tilley; Winkle Kwan
Journal:  J Cancer Surviv       Date:  2008-10-24       Impact factor: 4.442

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.